Annals of Surgical Oncology

, Volume 9, Issue 7, pp 668–674

Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials

  • Mark Bloomston
  • Emmanuel E. Zervos
  • Alexander S. RosemurgyII
Original Articles

DOI: 10.1007/BF02574483

Cite this article as:
Bloomston, M., Zervos, E.E. & Rosemurgy, A.S. Annals of Surgical Oncology (2002) 9: 668. doi:10.1007/BF02574483
  • 412 Downloads

Abstract

Matrix metalloproteinases (MMPs) have received much attention in recent years for their role in a variety of malignancies. Pancreatic cancer is no exception; MMP-2 and MMP-9 show high levels of expression in clinical and experimental models. Inhibition of MMPs has shown great promise with synthetic inhibitors, such as BB-94, as tumorostatic agents in preclinical models, particularly when these are combined with gemcitabine. These findings have led to several clinical trials using the MMP inhibitors Marimastat and BAY 12-9566. Herein, we discuss the roles of MMPs and their inhibition in pancreatic cancer.

Key Words

Pancreatic cancer Matrix metalloproteinase MMP TIMP 

Copyright information

© The Society of Surgical Oncology, Inc 2002

Authors and Affiliations

  • Mark Bloomston
    • 1
  • Emmanuel E. Zervos
    • 1
  • Alexander S. RosemurgyII
    • 1
  1. 1.Department of SurgeryUniversity of South FloridaTampa

Personalised recommendations